Skip to main content
Erschienen in: International Cancer Conference Journal 1/2024

31.08.2023 | Case Report - Complication

Two cases of dermatomyositis associated with neuroendocrine tumors

verfasst von: Uria Shani, Noy Lavine, Esther Houri-Levi, Abdalla Watad, Howard Amital

Erschienen in: International Cancer Conference Journal | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Dermatomyositis is an idiopathic inflammatory myopathy with cutaneous manifestations, which is associated with several types of malignancies, yet it has been rarely linked to neuroendocrine tumors (NETs). Here we report two cases of dermatomyositis associated with NETs of differing primary sites. Case 1: A 46-year-old female presented with a facial rash and proximal muscle weakness of both extremities. Investigations revealed elevated creatine kinase (CK) and positive anti-transcriptional intermediary factor 1-γ antibody (TIF1γ). The patient had been diagnosed with dermatomyositis and underwent a total body CT scan, which revealed prominent mediastinal lymphadenopathy, which a subsequent biopsy determined to be neuroendocrine carcinoma of small cell type. Treatment with high-dose corticosteroids was initiated, in addition to chemotherapy-based oncological management. Case 2: A 54-year-old female presented with a facial rash, progressive dyspnea, and general malaise. Laboratory investigations revealed positive anti-melanoma differentiation-associated gene-5 (MDA5) and positive anti-Ro antibody, with a normal level of creatine kinase (CK). A chest CT scan revealed multiple ground-glass opacities. Despite treatment with high-dose intravenous methylprednisolone, IVIG and an infusion of the anti-IL-6 sarilumab [Kevzara], the patient rapidly deteriorated and was intubated. Within days, the patient developed bowel ischemia and underwent a laparotomy which was then complicated by an invasive infection. This resulted in patient’s death. Pathology results from colonic tissue demonstrated an appendiceal neuroendocrine tumor. These cases demonstrate the heterogeneity and complexity of dermatomyositis in association with neuroendocrine tumors.
Literatur
1.
Zurück zum Zitat Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E et al (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17:816–828CrossRefPubMed Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E et al (2018) Classification and management of adult inflammatory myopathies. Lancet Neurol 17:816–828CrossRefPubMed
2.
Zurück zum Zitat Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353CrossRefPubMed Cobos GA, Femia A, Vleugels RA (2020) Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol 21:339–353CrossRefPubMed
3.
Zurück zum Zitat Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28:913–921CrossRefPubMed Sasaki H, Kohsaka H (2018) Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol 28:913–921CrossRefPubMed
8.
Zurück zum Zitat Shalata W, Zolnoorian J, Meirovitz A, et al (2022) Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience. Life (Basel, Switzerland) https://doi.org/10.3390/LIFE13010040 Shalata W, Zolnoorian J, Meirovitz A, et al (2022) Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience. Life (Basel, Switzerland) https://​doi.​org/​10.​3390/​LIFE13010040
9.
Zurück zum Zitat Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 21:131–136CrossRefPubMed Qiang JK, Kim WB, Baibergenova A, Alhusayen R (2017) Risk of malignancy in dermatomyositis and polymyositis: a systematic review and meta-analysis. J Cutan Med Surg 21:131–136CrossRefPubMed
11.
Zurück zum Zitat Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (United States) 19:991–1002CrossRef Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (United States) 19:991–1002CrossRef
12.
Zurück zum Zitat La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527–538CrossRefPubMed La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527–538CrossRefPubMed
13.
Zurück zum Zitat Lee WY, Kastelik J, Campbell A et al (2012) A case report of dermatomyositis associated with small cell lung cancer. Tumori 98:e158CrossRef Lee WY, Kastelik J, Campbell A et al (2012) A case report of dermatomyositis associated with small cell lung cancer. Tumori 98:e158CrossRef
14.
Zurück zum Zitat Yu K-L, Ho C-C (2016) Dermatomyositis as the initial presentation of small cell lung cancer: a case report. Thorac Med 31:215–221 Yu K-L, Ho C-C (2016) Dermatomyositis as the initial presentation of small cell lung cancer: a case report. Thorac Med 31:215–221
16.
Zurück zum Zitat Arnon J, Elia A, Nevo Y, et al (2021) SCLC, Paraneoplastic dermatomyositis, positive transcription intermediary factor 1-γ, and point mutation in the transcription intermediary factor 1-γ coding gene: a case report. JTO Clin Res Reports 2 Arnon J, Elia A, Nevo Y, et al (2021) SCLC, Paraneoplastic dermatomyositis, positive transcription intermediary factor 1-γ, and point mutation in the transcription intermediary factor 1-γ coding gene: a case report. JTO Clin Res Reports 2
17.
Zurück zum Zitat Kato T, Ito S, Tsuzuki T, et al (2019) Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. Respirol Case Reports 7 Kato T, Ito S, Tsuzuki T, et al (2019) Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. Respirol Case Reports 7
18.
Zurück zum Zitat Sheng-Hua Su, Yeh P-F, Te A, Kwang W-K (2014) Small cell lung cancer with paraneoplastic dermatomyositis: a case report. Thorac Med 29:377–383 Sheng-Hua Su, Yeh P-F, Te A, Kwang W-K (2014) Small cell lung cancer with paraneoplastic dermatomyositis: a case report. Thorac Med 29:377–383
28.
Zurück zum Zitat Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897PubMed Ceribelli A, Fredi M, Taraborelli M et al (2014) Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin Exp Rheumatol 32:891–897PubMed
30.
33.
Zurück zum Zitat dos Anjos CS, Lisita Rosa VD, Godoy ACC, et al (2015) Paraneoplastic dermatomyositis associated with neuroendocrine tumor of an unknown primary site: a case report. Clin Case Reports Rev 1 dos Anjos CS, Lisita Rosa VD, Godoy ACC, et al (2015) Paraneoplastic dermatomyositis associated with neuroendocrine tumor of an unknown primary site: a case report. Clin Case Reports Rev 1
Metadaten
Titel
Two cases of dermatomyositis associated with neuroendocrine tumors
verfasst von
Uria Shani
Noy Lavine
Esther Houri-Levi
Abdalla Watad
Howard Amital
Publikationsdatum
31.08.2023
Verlag
Springer Nature Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 1/2024
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-023-00629-3

Weitere Artikel der Ausgabe 1/2024

International Cancer Conference Journal 1/2024 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.